Azaindazole compounds as CCR1 receptor antagonists

US7879873B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Brian Nicholas Cook · Danbury, US
• Darren DiSalvo · New Milford, US
• Daniel Robert Fandrick · Danbury, US
• Christian Harcken · New Milford, US
• Daniel Kuzmich · Clovis, US
• Thomas Wai-Ho Lee · Danbury, US
• Pingrong Liu · Southbury, US
• John Lord · New York, US
• Can Mao · Philadelphia, US
• Jochen NEU · Mittelbiberach, DE
• Brian Christopher Raudenbush · Charlton, US
• Hossein Razavi · Danbury, US
• Jonathan Timothy Reeves · Ridgefield, US
• Jinhua J. Song · Brewster, US
• Alan David Swinamer · Bethel, US
• Zhulin Tan · Danbury, US

Key dates

• Filing date: Sep 22, 2009
• Grant date: Feb 1, 2011
• Expiry date: Sep 22, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.Also disclosed are methods of making and methods of using same.